The RET/GDNF signalling pathway plays a crucial role during development of
INTRODUCTION
Congenital abnormalities of the kidney and urinary tract (CAKUT) are frequently observed in children and represent a significant cause of morbidity, accounting for more than 40% of pediatric end-stage renal failure, and mortality. [1] Kidney development defects (KDD) include: (i) bilateral/unilateral renal agenesis (BRA/URA); (ii) renal hypodysplasia (RHD) characterized by a reduction in the number of nephrons leading to a small overall kidney size and frequent dysplasia with or without cysts; and (iii) multicystic dysplastic kidney (MCDK).
These various alterations can be observed together in a same patient or in different members of the same family, suggesting that they belong to a same continuum of phenotypes. Although most cases are sporadic and isolated, syndromic and familial cases suggest that genetic factors are involved. In particular, dominant mutations with variable penetrance have been found in several syndromic forms of KDD. The most frequently mutated genes are PAX2 in patients with renal-coloboma syndrome, EYA1 and SIX1 in patients with branchio-oto-renal (BOR) syndrome and HNF1B in patients with renal cysts and diabetes association. [2] [3] [4] [5] [6] Analysis of genotype-phenotype correlations showed that the severity of the renal disease associated with these mutations is extremely variable. [2, 7] Other less frequent syndromes including KDD are associated with mutations in developmental genes such as SALL1 (Townes-Brocks syndrome), WNT4 (Rokitanski syndrome), KAL1 (Kallman syndrome), FRAS1 and FREM1 (Fraser syndrome), GATA3 (RHD, hypoparathyroidism and sensorineural deafness) and GLI3 (Pallister-Hall syndrome). [8] [9] [10] [11] [12] [13] [14] Moreover, comparative genomic hybridization and familial studies have highlighted several chromosomal regions that could carry other genes involved in KDD. [15, 16] .
Mammalian kidney development results from a reciprocal induction between the ureteric bud (UB) and the metanephric mesenchyme (MM). Signalling by GDNF secreted by the MM and the RET tyrosine kinase receptor and its co-receptor GFRα1 expressed on the UB plays a critical role for normal growth and branching of the UB. [17, 18] The RET gene encodes two major splicing isoforms, RET9 and RET51, that differ in their carboxy terminus.
These two isoforms appear to have redundant roles for kidney development. [19, 20] The RET/GDNF signalling also plays a critical role during the development of the enteric nervous system. Homozygous knockout of Ret or Gdnf in mice leads to loss of enteric ganglia as well as severe kidney aplasia or hypodysplasia caused by a failure of UB outgrowth. [21, 22] In humans, heterozygous loss-of-function mutations in RET resulting in haploinsufficiency are the most frequent alterations reported in patients with segmental intestinal aganglionosis known as Hirschsprung disease (HSCR). [23, 24] RET is also an oncogene involved, through activating mutations, in predisposition to multiple endocrine neoplasia type 2A (MEN2A) characterized by medullary thyroid carcinoma (MTC), pheochromocytoma and/or parathyroid hyperplasia. [25] Several studies have reported the association of HSCR and MTC in patients with RET mutations affecting the cysteine-rich extracellular domain of the protein. Both activating and inactivating effects have been demonstrated for the C620R mutation (so called the Janus mutation) because, when expressed in kidney cells, it promotes cell proliferation and impairs migration and branching in three-dimensional culture in response to GDNF. [26] Interestingly, association of HSCR with CAKUT has also been described and a RET mutation has been reported in few cases, [27] suggesting a common genetic basis for these two pathologies. Renal agenesis was also reported in a family with MTC and the Janus RET C620 mutation. [28] Recently, both activating and inactivating RET mutations have been reported in a small series of fetuses with renal agenesis. [29] To better assess the role of the RET/GDNF signalling in KDD, we analysed coding and regulatory sequences of RET and GDNF in a series of 105 fetuses with severe bilateral defects.
PATIENTS AND METHODS

Patients
We studied a series of 105 fetuses with bilateral KDD contributing to anamnios or severe oligohydramnios and that had motivated termination of pregnancy. This included 65 cases with BRA, 24 cases with URA and an abnormal contralateral kidney (RHD in 8 cases, MCDK in 16 cases), 4 cases with bilateral RHD, 10 cases with bilateral MCDK, one case with RHD on one kidney and MCDK on the other and one case with URA and ureteral duplication. Kidney defects were defined by the fetopathologists of the Société Française de Foetopathologie upon histological examination. Five fetuses were from consanguineous families, 11 cases (including 4 sib-pairs) were from 7 non-consanguineous families in which the mother underwent several terminations of pregnancy for anamnios, and five other cases had relatives with renal abnormalities. Twenty-one fetuses had extra-renal abnormalities, namely uterine agenesis (6 cases), bifid uterus (1 case), epididymal hypoplasia or cysts (2 cases), or more complex syndromic associations (growth retardation, craniofacial dysmorphy, hand and limb anomalies, cardiopathy). No GLI3 mutation was identified in 3 fetuses with symptoms suggestive of Pallister-Hall syndrome. There was no indication of renal-coloboma or BOR syndromes in relatives of any of the studied fetuses. Moreover, we excluded the presence of HNF1B mutations / deletions in the fetuses with MCDK or RHD with cysts. 
Statistical analyses
Fisher exact tests were used to compare frequencies of the variants in patients and controls.
As 80% of the fetuses were of European origin, frequencies in controls were mostly evaluated by analysis of 189 unrelated Caucasians. Algerian and Turkish controls (34 and 33 cases, respectively) were also tested for polymorphisms present in patients originating from these countries. Moreover, we considered frequencies generated from the HapMap-CEU (120 chromosomes), Pilot. living children, with the same spectrum of bilateral KDD as the first series.
Analysis of RET cDNA
The effect of the c.1353 G>A variant (T451T) on splicing was analysed by RT-PCR, using primers located in exons 6 and 8. Quantitative RT-PCR was performed using the ABsolute Sybr green ROX mix (Thermo Scientific) and GAPDH was used as a control.
Analysis of copy number variations
For 41 samples, the quality and the available amount of DNA allowed us to perform genomic analysis on Illumina Infinium HumanOmni1 beadchips. Hybridizations were performed as recommended by the manufacturer. We used the GenomeStudio software for normalization and genotyping. For identification of copy number variations (CNVs), we used the GenomeStudio plug-in CNVpartition and the PennCNV algorithm with default parameters.
[30]
RESULTS
Analysis of RET
Sequencing of the 20 exons of RET in 105 fetuses with severe bilateral KDD identified 7 previously unreported variations in the coding region, including one nonsense mutation, four missense and two neutral changes ( Table 2 ). All variations were heterozygous and none of 8 them was identified in 180 controls. The nonsense mutation resulted in a stop codon located 58 and 16 amino acids before the C-terminus of RET51 and RET9 isoforms, respectively.
PolyPhen-2 predicted variations D567N and V787I as probably damaging with scores of 0.984 and 0.979 respectively and L56M as possibly damaging with a score of 0.281. Although R57Q was predicted as benign by PolyPhen-2, it was qualified as possibly damaging with the previous version of PolyPhen (score=1.558) and it affects a very conserved aminoacid.
For fetuses with the R57Q, D567N and W1056X mutations and the P992P neutral variant, DNA from the parents was available. In all four cases, the variation was also present in the heterozygous state in the father, in whom presence of the two normal-sized kidneys was ascertained by renal echography. This demonstrates that none of these variants alone, even the nonsense mutation, is sufficient to explain the renal development defect. Several variations corresponding to known SNPs were also identified in the coding sequence as well as in flanking intronic sequences. We compared their frequencies in the KDD fetuses to controls (Table 3A) . No significant difference was observed. Evolutionary sequence conservation has proven a valuable approach to identify genomic regions important for gene expression regulation. Using the ECR Browser (http://ecrbrowser.dcode.org), we identified 8 ECR regions that were at least 70% conserved until mouse (Table 1) . Six ECRs were located upstream of the transcript region (ECR1, -1B, -1E, -2, -4 and -8,) and sequencing of these ECRs in the 105 samples led to the identification of 11 variants (Table   3A) : five of them were referenced in the SNP database (http://www.ncbi.nlm.nih.gov/snp/)
and their frequencies were similar in cases and controls, whereas the 6 other were unreported variations that were heterozygous in 1% to 6% of the fetuses (allele frequencies between 0.005 and 0.03). We only identified the most frequent one, ECR2/504, in controls (Table 3A) .
ECR6 and ECR7 were located in intron 1 and included 7 variants that were all referenced in the SNP database. One of these variants, ECR6/271, was significantly more frequent in the KDD fetuses than in controls (heterozygous in 14/96 fetuses vs 7/189 controls, P=0.002) ( but also in fetuses and children with MCDK suggests that it could confer predisposition to the whole spectrum of KDD.
Sequencing of the 3'UTR of both RET9 and RET51 transcriptional isoforms revealed 8 referenced SNPs and 6 previously unreported rare variants (Table 3A) . There was no significant difference in their frequencies in cases vs. controls. 
Analysis of GDNF
Sequencing of GDNF coding and non-coding sequences identified 7 referenced SNPs and 6 unreported variants (Table 3B ). Variant frequencies in the fetuses were not different from those in controls. Therefore, this study did not provide any indication of the involvement of this gene in the etiology of KDD. (SPRY1, ROBO2, SLIT2) , the activator SOX9 and target genes ETV4 and ETV5. [32] [33] [34] For each gene, we analysed not only the gene itself but also surrounding sequences extending up to neighbouring genes on each side, in order to be sure to include regulatory sequences. In addition to two intronic CNVs, in SLIT2
and EYA1, each identified in 4 fetuses, we characterized a 1 kb heterozygous deletion spanning the GDNF non-coding exon 1 in one case. These three CNVs have been reported in controls (http://projects.tcag.ca/variation/), suggesting that they are polymorphic variations.
There was no CNV in any of the other tested genes.
DISCUSSION
The pattern of expression of RET and GDNF in fetal kidneys, the severe disruption of kidney development in Ret or Gdnf knockout mice, as well as large amounts of data generated from cellular and organ culture models, support the major role of the RET/GDNF signalling in control of branching morphogenesis during kidney development. [17, 18, [20] [21] [22] [35] [36] [37] [38] [39] Moreover, several RET mutations associated with MTC and/or HSCR have been shown to impair branching in a three-dimensional kidney cell culture model, [26, 40] in agreement with a role of RET in kidney morphogenesis. It was thus expected that mutations in RET and GDNF could be responsible for kidney development defects in human. Accordingly, heterozygous RET mutations were previously reported in 30% of a small series of 29 fetuses with BRA or URA and one heterozygous GDNF mutation in a fetus with URA. [29] However, our results, based on analysis of a larger series of 105 cases including 90 fetuses with either BRA or URA and contralateral RHD or MCDK do not confirm the high frequency of RET mutations in fetuses with renal agenesis or other severe abnormality of kidney development.
Discrepancy between the two studies could be explained by differences in the ethnic origin of the patients and/or by a bias due to the small number of patients in the study of Skinner et al..
We only report 7 potential mutations in the RET coding sequence (6.6%), and no mutation in the GDNF coding sequence. We did not analyse the sequence of the GDNF co-receptor encoding gene GFRA1 in this study because no mutation has ever been reported in this gene,
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neither in KDD nor in HSCR. [27, 29, 41] As reported, [29] the RET mutations that we identified in KDD fetuses were heterozygous, distributed all along the gene and most of them were missense variants. Only one nonsense mutation was identified and absence of tissue available for RNA and protein extraction precluded analysis of the impact of this mutation on the expression of the gene. As for HSCR, heterozygosity of the mutations suggests a mechanism based on haploinsufficiency, leading to a dysregulation of the RET signalling in kidney. However, one cannot exclude that some of the missense variants might be activating mutations with both gain-of-function and loss-of-function effects, as suggested for some of the mutations previously described. In addition to the 7 RET variations in the coding sequence, a total of 48 SNPs in coding and non-coding RET and GDNF sequences, as well as 21 new rare variants in non-coding sequences were identified in our series of fetuses (4 to 22 RET variants per fetus; 0 to 4 GDNF variant per fetus). This includes RET SNP variants A432A in exon 7 and G691S in exon 11, that have been reported as associated with CAKUT, [43, 44] and RET variants rs1864411, rs1864410, rs2435357 and rs2506004 in intron 1 that have been reported as part of a HSCR susceptibility haplotype. [45, 46] Based on the observation that allele frequencies in our cases were similar to controls, our data do not support a role in KDD for any of these variants. Four previously unreported variants in RET 5'-ECR regions were identified in a total of six patients and not in controls. However, the absence of clustering of these variants in one specific ECR is not in favour of a role in the dysregulation of RET expression. Moreover, discordant genotypes in the 3 pairs of fetuses belonging to families with recurrent KDD suggest that RET is not the culprit gene in these patients.
Interestingly, we identified one polymorphism in RET intron 1 (ECR6/271, rs2506012) with significant over-representation of the minor G allele in KDD fetuses. Analysis of transcription factor binding on the ECR6 sequence using the Genomatix genes, resulting in an altered gene regulation, have been reported in several pathologies. [48] [49] [50] In one case, the variation was a common polymorphism, significantly over-represented in patients vs. controls. [51] In the RET gene, a variant located in the 3'UTR has been reported to confer protection from HSCR. [52] However, sequencing of RET and GDNF 3'UTRs in KDD fetuses did not allow us to identify new variants nor variants with a higher frequency in patients vs. controls. When the micro-RNAs that regulate RET expression during kidney development are identified, it will be worthwhile screening for mutations in these sequences.
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Another genetic mechanism that could affect RET and/or GDNF expression and consequently kidney development is gene copy number variations. The only CNV of potential interest that we identified was a deletion spanning a CpG rich region and the non-coding exon 1 of GDNF. Although this CNV has been reported in normal controls (http://projects.tcag.ca/variation/), suggesting that it is a polymorphism, it could result in a decreased GDNF expression. However, it was present in only one fetus and thus cannot be considered as a significant event in KDD. Moreover, CNV analysis of 17 other genes encoding regulators or targets of the RET/GDNF pathway including the GDNF co-receptor encoding gene GFRA1, did not allow us to identify any CNV affecting these genes.
Altogether, this study clearly shows that RET and GDNF genomic alterations are not significantly associated with renal agenesis / hypodysplasia /multicystic dysplastic kidney in humans, suggesting that they play a minor role in KDD. These results are an important issue to be taken into account for genetic diagnosis of these defects. Interestingly, redundant receptor tyrosine kinase signalling, notably including FGF10/FGFR2, as well as a balance between positive and negative regulation of this signalling network, rather than RET/GDNF per se, was suggested to be the central pathway regulating branching for kidney development. [53] Regulatory or target genes common to these redundant signalling events could be worthwhile testing as new candidate genes to explain kidney development defects.
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